Member Info for Matml74

Maybe he can tell Iran to stop shooting at Isreal and vice versa so that it doesn’t effect the share price.

**** me you have 19 posts in the last month all moaning like a baby over your own investment decisions and you have one post removed and started two new subjects in one day based on your post getting removed.

get a life and grow up.

The man who is "cutting the fat" has bought significant amounts of shares (nearly 1% of the company) on the open market so he is very much aligned with shareholders to ensure no cash raise.

This company does not have a need to raise any further cash. Within the next 14 months the company reaches cashflow breakeven. Very easy for a CFO of Martin's considerable experience to manage cash, ensuring he is not diluted, in that situation.

The Magna note will be paid in shares, they will own 10% of the company and benefit from the the M&A consolidation of the market which will inevitably occur.

PS. Baxter stop starting a new subject every time you respond to a post....... Anyone cynical like me would think you are trying to push any of the excellent research of Terry and Seize and others down the page so no-one can find it!! The REPLY button is there for a reason!

CTSFO,

See that’s the problem with just using Google for research!

It’s not an error by Avacta at all. It still needs to be recorded as a DLT. You can’t just ignore an event like (cardiac arrest) happened …… but the whole idea of science is to explain the data and in this case from other information/data on the patients history it was determined by the SDMC that it was unlikely that the drug caused the event. Doesn’t mean it’s not recorded as a DLT. The continued study with no further cardiotoxicity showed they were correct.

An abstract is just a summary of data. In a full paper things like this are explained in detail.

Go and watch the science day presentation. The cardiotoxic events were described and was determined to be unrelated to the dosing of ava6000.

The patient who had from the 120mg cohort had grade 1 heart failure during the first cycle of treatment.

the company has told investors for years it had a long list of potential drugs it could potentially licence precision for…… none have eventuated, despite sitting on data since mid to late 2022 that showed the company precision was working.

the company had £60m quid from the cln in october 2022! it got ****ed up the wall on some hairbrained idea to go on a diagnostics buying spree when valuations post covid overvalued the businesses.

there are many ways this latest valuation and fundraise of the company at 50p could have been avoided but management and the board ****ed it up.

there are also plenty of companies that get drugs approved that go onto destroy shareholder value through company mismanagement and commercial inexperience …. stx anyone? getting the leadership right now is essential imo.

as is not ceo calibre for a company with the opportunity to change the landscape of oncology for high fap tumours.

“But the truth is the business has acquired the necessary resources to reach the key marker of proving the drug and commercialising it.”

The company doesn’t have anywhere near enough cash to commercialise the drug.

It has enough to get through the P2.

Licence or partnering of ava6000 or the platform are essential in this company driving any value for shareholders.

Extremely unlikely they can recruit quickly enough to complete by end of June in any case considering it has taken from September to basically the end of March to recruit 3 patients.

I don’t believe a new cohort can start without SDMC approving that the previous dosing regime is safe.

😂 Their PR is amazing though! 😂😂😂

Mobileye’s Supervision is not DMS! Go on their website and it explains what the system does.

They also had 200m in the bank and 3 drugs in the clinic, their own manufacturing plant and have been in partnership with AstraZeneca for 3 years…… so there was more to it than just presenting 3 posters at AACR.

“the dip in gross margins was an alarming to me”.

That is only due to the Magna exclusive licence wasn’t it?

The Magna cash has already been received. However there are many ways to skin a cat….

As noted below and highlighted by the CFO receivables financing is the backstop.

The Magna exclusive licence expires in 15 months so expect that to be extended considering they are already working on a Gen 2 mirror. That will likely happen in H125 and will be a nice lump of moula.

There are at least 3 new DMS auto programs beginning in 2024, including VW which started this month so the high margin royalties will start to make their mark.

Then there is Gen3. Even minimum traction in Europe with this in the next 2 quarters, followed by US and Australasia launch will ensure the company won’t have to ever worry about its cash position ever again!

"You should buy qed,......"

LOL. Clown. See QED just shafted their LTH again. Another placing at shocking discount which will barley keep the lights on.

Suggest you worry about a company you are actually are invested in for a change.

If only SP decrease correlated with dilution percentage, which is obviously nonsense.

The new investors valued the company at 50p (160m MCAP). Thinking this has anything to do with dilution percentage is delusional!

Excellent presentation. 3 months until year of cash break even!!Plenty of cash to see this through.

Answered honestly plenty of questions raised, options/RFQ's/minimum guarantee's etc etc unlike SEYE CEO who bluffs his way through and makes up the numbers on every award they have ever had.

why did it take simon bennett’s arrival to get the board to focus resources on therapeutic development.

it’s been clear to the vast majority that should have been the focus since the january 2023 data release and proof of mode of action of precision….. yet the company still went on to **** millions down the drain buying coris. the board are either clueless or have been really ******* slow at understanding where the true value was going to be generated.

£40m plus spent on diagnostics. 3996 would have been well into the clinic by now….. which was the plan, until someone on the board had the bright idea of a diagnostics m&a buying spree.

"Reckon up to Dec 2023 the BoD were willing to give away 3996 much too early and far too cheaply. "

The problem with this theory is that the company stated in 2022 that the following would happen......

" AVA3996 has been selected as a candidate for preclinical development. Clinical Trial Authorisation (CTA) and/or Investigational New Drug (IND) filing expected H1 2023 and dosing of the first patient later in 2023."

The company is unable, through inadequate management of resources, to develop out its pipeline in a timely manner to benefit shareholders.

So, how could they be giving it away to early when they are at least 2 years behind on the schedule that they identified for this molecule to get into the clinic? 3396 will not provide any value to shareholders for many years to come. It should already be in phase 1a dose escalation!

This company should be getting funds into to develop a long pipeline of Precision molecules to early clinical stage and execute a licensing strategy. Low risk high reward.

To think that this tiny team can get a drug to market by itself is extremely delusional.

It’s not all European cars. It’s new models which is a significantly lower number and contracts likely decided on those already.

A better question would be do SEE still anticipate 50% market share by value in automotive.

December 2023 presentation data shows prior history of treatment for patients. 3 of 40 had no prior cancer therapy.

…… more than 2 patients have shown a response!